455P A meta-analysis of efficacy and safety of cetuximab with biweekly vs. weekly dosing

Abstract

after 4 months 80.4AE17.3. Also, fatigue, appetite loss, and nausea/vomiting did not deteriorate over time. Final QoL results will be presented at the ESMO Congress.Conclusions: Overall survival in almost 500 patients from start of FTD/TPI is comparable to other population-based studies. Our results suggest that fewer symptoms at start of FTD/TPI treatment are associated with longer treatment duration. QoL was maintained during FTD/TPI treatment, which supports its use in clinical practice.Legal entity responsible for the study: The authors.

Cost-minimization analysis of biweekly dosing of cetuximab and FOLFIRI compared with panitumumab and FOLFOX for first-line treatment of patients with KRAS wild-type metastatic colorectal cancer in the United States

“…Similarly, a meta-analysis by Parikh et.al. reported similar efficacy and safety of biweekly versus weekly schedule and noted that biweekly dosing may potentially reduce the A c c e p t e d M a n u s c r i p t burden and cost of administration [19]. Also, patients with mCRC receiving biweekly cetuximab achieved similar overall survival (OS) to those administered weekly cetuximab [16,20,21].…”